Lineage Cell Therapeutics, Inc.
As of Oct 22, 2026, Lineage Cell Therapeutics is in Stage 4, the downtrend phase, now in week 23 (since May 12, 2026). It closed at $0.99, 49.5% below its 52-week high and below its 200-day average, which is falling.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is LCTX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
LCTX among Biotechnology315th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …315 | LCTX | Stage 4 · wk 23 | 28 | +3.1% |
Lineage Cell Therapeutics: quick answers
What stage is Lineage Cell Therapeutics in?
As of Oct 22, 2026, Lineage Cell Therapeutics (LCTX) is in Stage 4, the downtrend phase. It entered Stage 4 on May 12, 2026 and is in week 23. What the four stages mean
Is Lineage Cell Therapeutics in an uptrend?
No. Lineage Cell Therapeutics is in a Stage 4 downtrend. It trades 26.6% below its 200-day average, which is falling.
How far is Lineage Cell Therapeutics from its 52-week high?
Lineage Cell Therapeutics closed at $0.99 on Oct 22, 2026, 49.5% below its 52-week high of $1.96. Its 52-week low is $0.90.
How has Lineage Cell Therapeutics performed over the past year?
As of Oct 22, 2026, Lineage Cell Therapeutics is down 40.0% over the past year and down 39.6% so far in 2026.
Which sector and industry is Lineage Cell Therapeutics in?
Lineage Cell Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.